ライフサイエンスコーパス: blockade

1 nd EVL/VASP dKO T cells upon alpha4 integrin blockade.

2 effect) in the context of immune checkpoint blockade.

3 l on-treatment predictor of response to PD-1 blockade.

4 ting factor receptor or histamine receptor 1 blockade.

5 ere refractory to previous immune checkpoint blockade.

6 potentially important for immune checkpoint blockade.

7 g the functional outcome of combined pathway blockade.

8 ifferences were abrogated by sustained CD274 blockade.

9 res predictors of the response to checkpoint blockade.

10 se zeta (DGKzeta) with or without PD-1/PD-L1 blockade.

11 , late-phase LTP was also decreased by MMP-9 blockade.

12 n 17A, and are unresponsive to in vitro PD-1 blockade.

13 hen used in combination with systemic CTLA-4 blockade.

14 aking PMBCL particularly susceptible to PD-1 blockade.

15 make these tumors uniquely sensitive to PD-1 blockade.

16 drive systemic efficacy of immune checkpoint blockade.

17 creased the efficacy of anti-PD-1 checkpoint blockade.

18 enes that permit continued growth despite AR blockade.

19 SC to enhance responses to immune checkpoint blockade.

20 vels respond to GABA, but not NMDA, receptor blockade.

21 bine genotoxic agents with immune checkpoint blockade.

22 lculate the net rate of reversal of receptor blockade.

23 were able to demonstrate effective FcgammaR blockade.

24 explaining functional data collected on RyR blockade.

25 ment antitumor activity of immune checkpoint blockade.

26 on, and their efficacy was enhanced by PDL-1 blockade.

27 nts who show only a partial response to IL-1 blockade.

28 ia (PEI) and beta1 -adrenergic receptor (AR) blockade.

29 ulocyte-macrophage colony-stimulating factor blockade.

30 rgize with or cause resistance to checkpoint blockade.

31 through Cas9-mediated knockout and antibody blockade.

32 ance staircasing revealed that noradrenergic blockade (40 mg propranolol) significantly increased met

33 DBP-FITC was not affected by IFN-I receptor blockade, a finding consistent with the known dependence

34 er is significantly reduced by NMDA receptor blockade, a treatment that paradoxically enhances seizur

35 Blockade Ab avidity to the GI.1 vaccine component peaked

36 with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked early, with no increase in tit

37 mycolactone treatment, indicating that Sec61 blockade affects antigen cross-presentation indirectly.

38 by the combined actions of immune checkpoint blockade agents together with targeted agents that neutr

39 on to salutary actions due to direct beta1AR-blockade, agents such as metoprolol (Meto) may improve p

40 Neuromuscular blockade alone does not cause hypothermia but allowed ac

41 L-selectin blockade also demonstrated significant hepatoprotection

42 T-type current blockade also prevented synaptic potentiation induced by

43 Proposed mechanisms include neurohormonal blockade and heart rate reduction.

44 following its disruption by reconsolidation blockade and inhibition of PKM.

45 olony-stimulating factor 1 receptor (CSF-1R) blockade and nanoparticle-based drug delivery in murine

46 ll, our data suggest the combination of PD-1 blockade and oHSV-1 may be an effective treatment strate

47 hypoxaemic patients with ARDS, neuromuscular blockade and prone positioning have further reduced mort

48 plex nature of immune response to checkpoint blockade and the compelling need for greater interrogati

49 mice that the same tolerizing protocol (CD4 blockade) and the same target Ag (OVA) achieves Foxp3-de

50 referred to generically as immune checkpoint blockade, and conversely to treat autoimmunity and CTLA-

51 growth potential upon escape from cell-cycle blockade, and is enriched in relapse tumours.

52 Strikingly, although combination checkpoint blockade (anti-CTLA-4 + anti-PD-1) was ineffective again

53 nt melanomas, the addition of MDSC depletion/blockade (anti-Gr-1 + CCR2 antagonist) prevented outgrow

54 changes in GII.17 strains result in loss of blockade antibody binding, indicating that viral evoluti

55 Immune checkpoint blockade appears to be a promising approach for patients

56 doptive T-cell transfer or immune checkpoint blockade, arguing for an adaptive resistance mechanism.

57 wo studies support further evaluation of IFN blockade as a supplement to ART.

58 and they identify TNFalpha and TGFbeta1 dual blockade as an antimetastatic strategy in solid tumors.

59 We observe current blockade at room temperature in thousands of single-clus

60 ells was initially reversible by PD-1 ligand blockade, but it progressively developed into an irrever

61 Mechanistically, PI3K blockade by BKM120 attenuated HR competency with gammaH2

62 t that AT1R knockdown and AT1R pharmacologic blockade by losartan may differently control balance of

63 Error-prone polymerases overcome this blockade by synthesizing past DNA lesions in a process c

64 pe IL-23 except for binding of and signaling blockade by the 7B7 anti-IL-23 antibody.

65 A-mediated PPARalpha silencing and PPARalpha blockade by the antagonist GW6471 abolish the effect of

66 cur through bypass of androgen receptor (AR) blockade by the glucocorticoid receptor (GR).

67 ltogether, these findings suggest that VEGFR blockade by tivozanib has potential anti-glioma effects

68 Blockade, by either monoclonal antibody or tumor necrosi

69 mune repertoire immediately after checkpoint blockade can be both detrimental and beneficial for pati

70 models suggest that oestrogen and dofetilide blockade can concur simultaneously in the hERG channel p

71 To investigate whether partial neuromuscular blockade can facilitate lung-protective ventilation whil

72 B "addiction" of Ph(+) ALL.Significance: MYB blockade can suppress Philadelphia chromosome-positive l

73 This suggests that anti-IL-6/IL-6R blockade could be effective in modifying T- and B-cell r

74 R had prognostic significance, suggesting AR blockade could be employed therapeutically.

75 ion by control keratinocytes, and type I IFN blockade decreased IL-6 secretion by lupus keratinocytes

76 These data demonstrate that CD47mAb blockade decreases IRI and subsequent tissue injury in D

77 PD-1 blockade delays tumor growth without changing TIL metabo

78 m bioluminescence recordings, GABAA receptor blockade desynchronized the Fbxl3(+/+) but not the Fbxl3

79 Beta-receptor blockade does not alter the tachycardia phase to low int

80 er DNA damaging chemotherapy, whereas single blockade does not.

81 can reverse gut inflammation, while cytokine blockade during NLRP12 deficiency can reverse dysbiosis.

82 mportantly, the pathogenic effects of IL-10R blockade during P. berghei ANKA infection were reversibl

83 se, and administration of alpha1 -adrenergic blockade elevated FMD (P = 0.032).

84 While immune checkpoint blockade elicits efficacious responses in many patients

85 ghly resistant to anti-VEGFR2 therapy, CXCR4 blockade enhanced anti-VEGFR2-induced tumor growth delay

86 Finally, alpha5beta1 blockade enhanced the effect of the bronchodilator isopr

87 In human artery-SCID chimeras, PD-1 blockade exacerbated vascular inflammation, enriched for

88 Partial neuromuscular blockade facilitates lung-protective ventilation during

89 ng with ISF35 in combination with checkpoint blockade for multifocal cancer, including the brain.

90 ors develop new onset psoriasis and why IL-6 blockade for the treatment of psoriasis has not been cli

91 Our aim was to determine whether TNF-alpha blockade has a beneficial effect on endothelial function

92 itoring of responders to clinical checkpoint blockade has been the lack of imaging tools to accuratel

93 Immune checkpoint blockade has emerged as a promising cancer treatment par

94 Immune checkpoint blockade has revolutionized cancer treatment.

95 Combinatorial studies with immune checkpoint blockade have started and the results are awaited with g

96 ath 1/programmed death ligand 1 (PD-1/PD-L1) blockade, have improved the treatment of non-small-cell

97 Similarly, on mTOR blockade, hMSCs also enhanced their immunoregulatory fea

98 int blockade immunotherapy.Immune checkpoint blockade (ICB) therapies can unleash anti-tumour T-cell

99 Immune-checkpoint-blockade (ICB)-mediated rejuvenation of exhausted T cell

100 Checkpoint blockade immunotherapies enable the host immune system t

101 Cytokine and immune checkpoint blockade immunotherapy for metastases was compromised wh

102 ecific T cells and the effects of checkpoint blockade immunotherapy.Immune checkpoint blockade (ICB)

103 tor (CB1R) induces nephropathy, whereas CB1R blockade improves kidney function.

104 These findings might help to explain why TNF blockade improves lung function in only some patients wi

105 In this near-complete response to PD-1 blockade in a mesenchymal tumor, we identified PTEN muta

106 otential effect of an antibody-mediated CD47 blockade in a syngeneic and an allogeneic DCD rat kidney

107 the immunological responses induced by PD-1 blockade in cancer patients is lacking.

108 and the success of programmed death 1 (PD-1) blockade in classical Hodgkin lymphoma (cHL) patients, a

109 Importantly, Notch blockade in combination with chemotherapy suppresses tum

110 be an important resistance mechanism to CCR5 blockade in GVHD.

111 y demonstration of JAK-STAT and HDAC pathway blockade in hematological cell lines.

112 ark clinical trials investigating checkpoint blockade in lung cancer and mesothelioma is provided.

113 or the antitumor effect of immune checkpoint blockade in mice.

114 res are associated with the response to PD-1 blockade in other tumour types.

115 a Friend retrovirus infection model, CTLA-4 blockade in particular was able to improve control of vi

116 this study to evaluate the efficacy of PD-1 blockade in patients with advanced mismatch repair-defic

117 cal response rate and efficacy of PD-1-PD-L1 blockade in patients with cancer.

118 Acute trkB blockade in rats with stable nigrostriatal denervation a

119 In addition, IFNgamma blockade in T cell/VEC coculture increased VEC prolifera

120 TL and support further investigation of PD-1 blockade in these diseases.

121 To determine the role of OCT3 blockade in these effects, we examined the abilities of

122 igned to clarify the therapeutic value of CP blockade in transplantation.

123 siological relevance of LGR5 internalization blockade in vivo A LGR5-rainbow (LBOW) mouse line was en

124 of ionizing radiation and immune checkpoint blockade in vivo.

125 PD-1 blockade increased the size of subdominant TCD8 clones a

126 of CD4(+) T lymphocytes by immune checkpoint blockade increased vessel normalization.

127 astasis, a combination of MSC-oHSV and PD-L1 blockade increases IFNgamma-producing CD8(+) tumor-infil

128 umors to PD-1/programmed cell death ligand 1 blockade-induced rejection.

129 ng integrin in ASM, and alpha5beta1-specific blockade inhibited focal adhesion phosphorylation and IL

130 In vitro, IL-4 blockade inhibited while addition of exogenous IL-4 to T

131 g single-agent renin-angiotensin-aldosterone blockade is accompanied by improved cardiorenal outcomes

132 rogeneity, and successful response to CSF-1R blockade is characterized by enhanced TAM penetration th

133 mmability (for example, to immune checkpoint blockade) is not well understood.

134 ally evaluated oncolytic viruses and to PD-1 blockade, LCMV treatment shows promising antitumoural be

135 ed cycle length and rescued the progesterone blockade LH surge, while RU486 into the ARC shortened LH

136 During beta1 -AR blockade, LV volumes were unchanged but blood pressure a

137 Selective CP blockade may be a promising strategy to counteract rejec

138 Our results indicate that FGF/MAPK blockade may be particularly efficacious against mPCs wi

139 The mechanisms by which immune checkpoint blockade modulates tumor evolution during therapy are un

140 ming de novo resistance to immune checkpoint blockade, motivating a search for targeted therapies tha

141 eficiency and was rescued by pharmacological blockade of adenylate cyclase.

142 Blockade of AhR using a clinically available AhR antagon

143 RNAi-mediated blockade of AKT, HSF1 or HuR is sufficient to downregula

144 onses, a disruption that resulted from local blockade of alpha7-nicotinic acetylcholine receptors (al

145 These findings establish blockade of alpha9-containing nAChRs as the basis for th

146 Blockade of any of these steps causes hyperproliferation

147 The blockade of astrocytic CN/NFAT signaling in a common mou

148 Blockade of AT1R signaling has been shown to alleviate h

149 inhibitors of B7-related molecules and CD40, blockade of B cell function and B cell survival factors,

150 Dclre1c(leaky) mice present with a complete blockade of B-cell differentiation, with a leaky block i

151 nd tumor formation was completely blunted by blockade of beta-adrenergic signaling in MCF-7 cells, in

152 Indeed, with dual blockade of both pathways by Atg5(-/-) and dominant-nega

153 c response are achieved only by simultaneous blockade of both receptors.

154 in mediating epithelial injury; and that the blockade of C' receptors mitigates lung fibrosis.

155 In a proof-of-concept in vivo experiment, blockade of C1q and C3a transiently altered hNSC migrati

156 In vivo blockade of CD40 ligand attenuated B-cell abnormalities

157 eral immune therapies requires near-complete blockade of CD47 in the tumor microenvironment.

158 Modulation of nitric oxide activity through blockade of CD47 signaling has been shown to reduce isch

159 Blockade of Chrm1 in the CNS, but not the periphery, red

160 Inhibition of cathepsin S molecules, blockade of costimulation through administration of abat

161 ifference is normalized with pharmacological blockade of CRF1 receptors.

162 Blockade of CXCR4 signaling significantly enhanced treat

163 tion of Clec7a-the gene encoding dectin 1-or blockade of dectin 1 downstream signaling was protective

164 um, and the highly selective pharmacological blockade of either iPLA2gamma or lipoxygenases attenuate

165 However, blockade of either single receptor through the use of sp

166 oreceptor denervation and by pharmacological blockade of either sympathetic - propranolol - or parasy

167 sed from HCV-infected hepatocytes given that blockade of exosome-associated TGF-beta or inhibition of

168 d levels of malonyl-CoA, as occurs following blockade of FASN, suggesting new targeted strategies in

169 ion from injury is achieved by pharmacologic blockade of FcRn-albumin interactions with monoclonal an

170 scaling down of mEPSC amplitudes after 48 h blockade of GABAA R-mediated inhibition with bicuculline

171 In vivo blockade of Gal-3 with N-acetyl-d-lactosamine in T. cruz

172 neurotransmission, persisted during partial blockade of gap junctions and were mediated, in part, by

173 Moreover, we find that blockade of gap junctions or ablation of Cx36 significan

174 Pharmacological blockade of gap junctions or genetic ablation of connexi

175 mone-mediated release of the transcriptional blockade of genes associated with cell cycle progression

176 Pharmacological blockade of GH signaling prevented the development of th

177 Blockade of GNA13 expression, or of select downstream pa

178 However, systemic blockade of HCN channels produces cardiac effects that l

179 The mechanism of DNA damage-induced blockade of HIV-1 infection involved activation of p53,

180 eviously discovered that a pathogen-mediated blockade of host protein synthesis provokes the producti

181 Blockade of ICOSL rescues T cell ICOS surface expression

182 Blockade of IFN response factor 7 nuclear translocation

183 Blockade of IFN-alpha but not IFN-beta signaling using e

184 humanized mice, we demonstrated that in vivo blockade of IFN-I signaling during chronic HIV infection

185 Full blockade of IGF-1R affected female and male mice similar

186 Moreover, blockade of IGF-2 by MEDI-573 modulated other signaling

187 (+) inflammatory monocytes and pharmacologic blockade of IL-1beta or NLRP3 abrogated this phenotype.

188 We used blockade of IL-21 to dissect the mechanisms by which thi

189 To examine whether targeted blockade of IL-23 or IL-17A in KC-Tie2 psoriasis mice im

190 We propose that blockade of IL-23 should have a therapeutic value in pat

191 Hyperglycemia or blockade of insulin signaling reduces the expression of

192 Therefore, selective blockade of interleukin-23 via inhibition of p19 might b

193 In this phase 2 trial, selective blockade of interleukin-23 with risankizumab was associa

194 Blockade of JAK2/STAT3 and TGF-beta signaling by specifi

195 Blockade of KIR channels alone or in combination with NO

196 In cultured dorsal spinal neurons, blockade of Kv3.4 by blood depressing substance II suppr

197 Pharmacological blockade of LDTg GLP-1Rs with exendin-(9-39) dose-depend

198 Combined blockade of local GABAARs and KORs resulted in complete

199 Pharmacological blockade of lymphangiogenesis via VEGFR-3 inhibition res

200 whereas genetic knockdown or pharmacological blockade of microRNA-146a blunted the hypertrophic respo

201 Blockade of muscarinic receptors had no effect on evoked

202 The finding that blockade of muscarinic receptors in mPFC impaired trace

203 On this background, we speculated that blockade of Na/K-ATPase-induced ROS amplification with a

204 d microvascular perfusion in response to the blockade of NET-induced coagulation, which correlated wi

205 ather, GR activation resulted in genome-wide blockade of NF-kappaB interaction with chromatin and dir

206 eling in promoter regions of specific genes, blockade of NF-kappaB pathway activation, and modulation

207 Ablation of Dclk1(+) cells or blockade of NGF/Trk signaling inhibited epithelial proli

208 Blockade of NKCC1 after SE with the specific inhibitor b

209 Pharmacological blockade of NOD1 also prevented Ca(2+) mishandling in wt

210 ancer cell lines of diverse tissue origin by blockade of nuclear FOXO4 degradation and induction of c

211 potentiates cocaine-primed reinstatement by blockade of OCT3.

212 mmation, genetic deletion or pharmacological blockade of OSM significantly attenuates colitis.

213 Pharmacological blockade of outward chloride transport had no effect dur

214 noids from the isogenic iPSCs and found that blockade of p25 generation reduced levels of phosphoryla

215 Unilateral blockade of P2Y1 receptors in the preBotC via local anta

216 Blockade of p75 cleavage using a specific inhibitor sign

217 Blockade of PD-L1/CTLA4 signaling dampened activation of

218 local GABAARs and KORs resulted in complete blockade of PFC-induced heterosynaptic suppression of le

219 sregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTO

220 We show that blockade of PKA binding to AKAPs in the nucleus accumben

221 This blockade of PKR function is highly specific, as LCMV is

222 In SMA mice or after the blockade of proprioceptive synaptic transmission, we obs

223 blation of Adrb1 in haematopoietic cells, or blockade of PSGL-1, the receptor involved in neutrophil-

224 Blockade of Runx2 inhibited the house dust mite-induced

225 Blockade of sensory input before movement prevented BTP,

226 Furthermore, we found that blockade of STAT3 signaling downregulated PD-1/PD-L1 in

227 proinflammatory cytokines with a concordant blockade of T cell-mediated responses.

228 Blockade of T-type currents prevents the induction of lo

229 roles in progression of renal fibrosis, dual blockade of TGF-beta1 and TNF-alpha is desired as its th

230 We investigated whether blockade of the CD47 signaling pathway could reduce isch

231 d 2 in neonatal cholangiocytes in vitro, and blockade of the corresponding chemokine (C-C motif) rece

232 Blockade of the GIRK current by Ba(2+) or Tertiapin-Q di

233 ein kinase 1 (PAK1) to HER2, resulted in the blockade of the HER2-pY(1196)-PAK1-T(423) signaling path

234 infection by multiple mechanisms: (i) direct blockade of the interaction between the gp120 exterior e

235 Blockade of the PD-1/PD-L1 immune checkpoint pathway wit

236 ere weak and could only partly be rescued by blockade of the programmed death 1 pathway.

237 effects were not accompanied by significant blockade of the Raf/Mek/Erk pathway, but rather by reduc

238 avenger receptors (SRs; MARCO and SR-B1), as blockade of the receptors with antibodies or siRNA knock

239 experimental and behavioral biomarkers, that blockade of the V1a receptor may improve social communic

240 lammatory pathways on cardiac reprogramming, blockade of these pathways with anti-inflammatory drugs

241 st novel therapeutic strategies based on the blockade of this CD84-dependent survival pathway.

242 n of CCK-induced pancreatic injury, and that blockade of this secretory process could increase autoph

243 O-specific naive and memory T cells, whereas blockade of TIM-3 produced no effect.

244 Similarly, antibody blockade of TLR2, TLR4, or C5aR differentially inhibited

245 CCM formation, and genetic or pharmacologic blockade of TLR4 signalling prevents CCM formation in mi

246 In addition, blockade of trkB unexpectedly reduced the functional ben

247 Pharmacological blockade of TRPM7 with NS8593 or waixenicin A in wild-ty

248 litudes and GluA1 synaptic levels after 48 h blockade of type A GABA receptor (GABAA R)-mediated inhi

249 ymphocytic choriomeningitis virus infection, blockade of type I IFN signaling partially restores anti

250 Blockade of VEGFR-2 signaling suppressed these vascular

251 Blockade of vesicular exocytosis in preBotC astrocytes b

252 monocytes secreted high levels of IL-6, the blockade of which resulted in increased neutrophil recru

253 ith nonclassical/intermediate monocytes, the blockade of which significantly reduced neutrophil recru

254 required for WSS-enhanced cell movement, as blockade of YAP1, TEAD1-4 or the YAP1-TEAD interaction r

255 Genetic or chemical blockades of JNK and MMP1 suppressed metastatic dissemin

256 Loss, or blockade, of NaV 1.7 did not affect afferent responses t

257 onvergent mechanisms of PI3Kalpha and CDK4/6 blockade on cell-cycle progression, DNA damage response,

258 to examine the effects of beta-adrenoceptor blockade on immediate and delayed extinction learning.

259 istically, prevention of puberty by hormonal blockade or acceleration of puberty by oestrogen treatme

260 or cell types was assessed based on receptor blockade or depletion.

261 While PD-1 blockade or IL10 neutralization as monotherapies were in

262 ch, alone and in combination with checkpoint blockade or other immunotherapies.

263 PD-1 inhibitory receptor blockade partially reversed T cell unresponsiveness.

264 PD-1 blockade post-allo-HCT should be studied further but can

265 ing current injection, but not AMPA receptor blockade, prevents synaptic stimulation from facilitatin

266 budesonide 16 mg/day, added to optimised RAS blockade, reduced proteinuria in patients with IgA nephr

267 ers make them sensitive to immune checkpoint blockade, regardless of the cancers' tissue of origin.

268 l effect of D2 receptor (D2R) stimulation or blockade remains highly controversial, with studies show

269 that microenvironmental alteration by CSF-1R blockade renders tumor cells more susceptible to recepto

270 tion or renin-angiotensin-aldosterone system blockade result in better preservation of intermediate-t

271 HER2)-positive breast cancers with dual HER2 blockade resulted in increased pathologic complete respo

272 n and murine tumors following VEGF signaling blockade, resulting in recruitment of CX3CR1+Ly6Clo mono

273 alternative pathways and canonical autophagy blockade, results in dramatic nuclear pathology with dis

274 ell growth media conditioned after autophagy blockade revealed levels of secreted IL6, IL8, and other

275 e improved viability of Huh7.5A2 cells, PD-1 blockade reversed this effect, producing enhanced cytoly

276 R3/4 was revealed by shRNA knockdown and mAb blockade, showing that these regulatory receptors limit

277 SK channel blockade slows repolarization and subsequent depolarizat

278 al mesothelial cells (PMCs) showed that CTGF blockade suppressed TGF-beta1-induced fibroblast prolife

279 eosinophil viability via strategic cytokine blockade, the molecular mechanisms underlying differenti

280 dditional immunotherapies such as checkpoint blockades, the nanovaccine demonstrates substantial ther

281 nation with other existing immune checkpoint blockade therapies.

282 Immune checkpoint blockade therapy (ICBT), which blocks negative immune-ac

283 rom two clinical trials of immune checkpoint blockade therapy for metastatic melanoma, we found that

284 logical recordings, and cholinergic receptor blockade to delineate the cholinergic contributions to p

285 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cance

286 ADRB2 blockade together with gemcitabine reduced NGF expressio

287 l expansion and clonal diversity during PD-1 blockade treatment.

288 antibodies achieves only a partial signaling blockade upon myostatin or activin A stimulation, and th

289 d sucrose seeking in the absence of mGluR2/3 blockade was not affected by blocking mGluR5.

290 ed with an increase in RUNX1 expression; the blockade was overcome by a RUNX1 inhibitor.

291 otentiated sucrose reinstatement by mGluR2/3 blockade was reversed by antagonizing mGluR5, but reinst

292 topoietic tumour cells during SIRPalpha-CD47 blockade was strictly dependent on SLAM family receptors

293 ce ameliorated the antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed

294 involving optimized renin-angiotensin system blockade, which might generate further uncertainty in th

295 ic melanoma tumors taken prior to checkpoint blockade, which revealed biological signatures that can

296 Combining MYC blockade with PARPi yielded synthetic lethality in MYC-d

297 inflamed and responsive to immune checkpoint blockade with programmed death 1 (PD-1) targeted agents,

298 e have shown that systemic beta-adrenoceptor blockade with propranolol rescues the IED, but impairs d

299 ne breast cancer model indicates that double blockade with two immune checkpoint inhibitors increases

300 e pore (sensing zone), which results in pore blockades with unique and easily distinguishable serrate